Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Bruno Emanuel Ferreira De Sousa CorreiaThroughout my PhD and postdoctoral studies I was trained in world-renowned laboratories and institutions in the United States of America (University of Washington and The Scripps Research Institute). Very early in my scientific career I found out my fascination about protein structure and function. My PhD studies evolved in the direction of immunogen design and vaccine engineering which sparked my interest in the many needs and opportunities in vaccinology and translational research. My efforts resulted in an enlightening piece of work where for the first time, computationally designed immunogens elicited potent neutralizing antibodies. During my postdoctoral studies I joined a chemical biology laboratory at the Scripps Research Institute. In this stage I developed novel chemoproteomics methods for the identification of protein-small molecule interaction sites in complex proteomes. In March 2015, I joined the École Polytechnique Fédérale de Lausanne (EPFL) – Switzerland as a tenure track assistant professor. The focus of my research group is to develop computational tools for protein design with particular emphasis in applying these strategies to immunoengineering (e.g. vaccine and cancer immunotherapy). The activities in my laboratory focus on computational design methods development and experimental characterization of the designed proteins. Our laboratory has been awarded with 2 prestigious research grants from the European Research Council. Lastly, I have been awarded the prize for best teacher of Life sciences in 2019.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
John McKinneyProfessor John McKinney received his Ph.D. from The Rockefeller University (New York, NY) in 1994 for studies on cell cycle regulation in
Saccharomyces cerevisiae
in the laboratory of Fred Cross. From 1995 to 1998, he was a postdoctoral fellow in the laboratory of William Jacobs at the Albert Einstein College of Medicine (Bronx, NY), where he studied mechanisms of persistence in
Mycobacterium tuberculosis
. In 1999, he returned to Rockefeller University to establish his own laboratory as an Assistant (1999-2004) and then Associate (2004-2007) Professor. In July 2007, the lab relocated to the Global Health Institute in the School of Life Sciences at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, where McKinney is Professor and Head of the Laboratory of Microbiology and Microsystems (LMIC). Our research focuses on understanding the mechanistic basis of bacterial persistence in the context of host immunity and antimicrobial therapy, using
M. tuberculosis
as a "model" system.
Jean-Yves Le BoudecJean-Yves Le Boudec is full professor at EPFL and fellow of the IEEE. He graduated from Ecole Normale Superieure de Saint-Cloud, Paris, where he obtained the Agregation in Mathematics in 1980 (rank 4) and received his doctorate in 1984 from the University of Rennes, France. From 1984 to 1987 he was with INSA/IRISA, Rennes. In 1987 he joined Bell Northern Research, Ottawa, Canada, as a member of scientific staff in the Network and Product Traffic Design Department. In 1988, he joined the IBM Zurich Research Laboratory where he was manager of the Customer Premises Network Department. In 1994 he joined EPFL as associate professor. His interests are in the performance and architecture of communication systems. In 1984, he developed analytical models of multiprocessor, multiple bus computers. In 1990 he invented the concept called "MAC emulation" which later became the ATM forum LAN emulation project, and developed the first ATM control point based on OSPF. He also launched public domain software for the interworking of ATM and TCP/IP under Linux. He proposed in 1998 the first solution to the failure propagation that arises from common infrastructures in the Internet. He contributed to network calculus, a recent set of developments that forms a foundation to many traffic control concepts in the internet. He earned the Infocom 2005 Best Paper award, with Milan Vojnovic, for elucidating the perfect simulation and stationarity of mobility models, the 2008 IEEE Communications Society William R. Bennett Prize in the Field of Communications Networking, with Bozidar Radunovic, for the analysis of max-min fairness and the 2009 ACM Sigmetrics Best Paper Award, with Augustin Chaintreau and Nikodin Ristanovic, for the mean field analysis of the age of information in gossiping protocols. He is or has been on the program committee or editorial board of many conferences and journals, including Sigcomm, Sigmetrics, Infocom, Performance Evaluation and ACM/IEEE Transactions on Networking. He co-authored the book "Network Calculus" (2001) with Patrick Thiran and is the author of the book "Performance Evaluation of Computer and Communication Systems" (2010).
